Breast MRI in patients after breast conserving surgery with sentinel node procedure using a superparamagnetic tracer
Open Access
- 27 January 2022
- journal article
- research article
- Published by Springer Nature in European Radiology Experimental
- Vol. 6 (1) , 1-9
Abstract
Background: A procedure for sentinel lymph node biopsy (SLNB) using superparamagnetic iron-oxide (SPIO) nanoparticles and intraoperative sentinel lymph node (SLN) detection was developed to overcome drawbacks associated with the current standard-of-care SLNB. However, residual SPIO nanoparticles can result in void artefacts at follow-up magnetic resonance imaging (MRI) scans. We present a grading protocol to quantitatively assess the severity of these artefacts and offer an option to minimise the impact of SPIO nanoparticles on diagnostic imaging. Methods: Follow-up mammography and MRI of two patient groups after a magnetic SLNB were included in the study. They received a 2-mL subareolar dose of SPIO (high-dose, HD) or a 0.1-mL intratumoural dose of SPIO (low-dose, LD). Follow-up mammography and MRI after magnetic SLNB were acquired within 4 years after breast conserving surgery (BCS). Two radiologists with over 10-year experience in breast imaging assessed the images and analysed the void artefacts and their impact on diagnostic follow-up. Results: A total of 19 patients were included (HD, n = 13; LD, n = 6). In the HD group, 9/13 patients displayed an artefact on T1-weighted images up to 3.6 years after the procedure, while no impact of the SPIO remnants was observed in the LD group. Conclusions: SLNB using a 2-mL subareolar dose of magnetic tracer in patients undergoing BCS resulted in residual artefacts in the breast in the majority of patients, which may hamper follow-up MRI. This can be avoided by using a 0.1-mL intratumoural dose.Keywords
Funding Information
- Stichting voor de Technische Wetenschappen
- Interreg (122207)
This publication has 24 references indexed in Scilit:
- Sentinel lymph node identification using superparamagnetic iron oxide particles versus radioisotope: The French Sentimag feasibility trialJournal of Surgical Oncology, 2016
- Sentinel lymph nodes for breast carcinoma: an update on current practiceHistopathology, 2015
- Superparamagnetic iron oxide as a tracer for sentinel node biopsy in breast cancer: A comparative non-inferiority studyEuropean Journal of Surgical Oncology, 2015
- 4. Analysis of void artefacts in post-operative breast MRI due to residual SPIO after magnetic SLNB in SentiMAG Trial participantsEuropean Journal of Surgical Oncology, 2015
- Magnetic sentinel node and occult lesion localization in breast cancer (MagSNOLL Trial)British Journal of Surgery, 2015
- The superparamagnetic iron oxide is equivalent to the Tc99 radiotracer method for identifying the sentinel lymph node in breast cancerEuropean Journal of Surgical Oncology, 2015
- Novel techniques for sentinel lymph node biopsy in breast cancer: a systematic reviewThe Lancet Oncology, 2014
- The Central-European SentiMag study: Sentinel lymph node biopsy with superparamagnetic iron oxide (SPIO) vs. radioisotopeThe Breast, 2014
- Sentinel Node Biopsy Using a Magnetic Tracer Versus Standard Technique: The SentiMAG Multicentre TrialAnnals of Surgical Oncology, 2013
- Dual Contrast Enhanced Magnetic Resonance Imaging of the Liver with Superparamagnetic Iron Oxide Followed by Gadolinium for Lesion Detection and CharacterizationClinical Radiology, 2001